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Abstract
Tumor development is accompanied by a complex host systemic response, which includes inflammatory and angiogenic
reactions. Both tumor-derived and systemic response proteins are detected in plasma from cancer patients. However, given
their non-specific nature, systemic response proteins can confound the detection or diagnosis of neoplasia. Here, we have
applied an in-depth quantitative proteomic approach to analyze plasma protein changes in mouse models of subacute
irritant-driven inflammation, autoreactive inflammation, and matrix associated angiogenesis and compared results to
previously described findings from mouse models of polyoma middle T-driven breast cancer and Pdx1-Cre Kras
G12D Ink4a/
Arf
lox/lox -induced pancreatic cancer. Among the confounding models, approximately 1/3 of all quantified plasma proteins
exhibited a significant change in abundance compared to control mice. Of the proteins that changed in abundance, the
majority were unique to each model. Altered proteins included those involved in acute phase response, inflammation,
extracellular matrix remodeling, angiogenesis, and TGFb signaling. Comparison of changes in plasma proteins between the
confounder models and the two cancer models revealed proteins that were restricted to the cancer-bearing mice, reflecting
the known biology of these tumors. This approach provides a basis for distinguishing between protein changes in plasma
that are cancer-related and those that are part of a non-specific host response.
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Introduction
The effective treatment of cancer relies on an accurate diagnosis
at the earliest stage of the disease and prognosis is significantly
improved if cancer is detected early [1]. Blood-based tests for early
detection of cancer are ideal, given that blood draws are
inexpensive, minimally invasive, and routine in clinical practice.
While the concept of a blood-based cancer test is simple, its
application has been challenging, to the point that very few new
cancer biomarkers have been FDA approved in recent years [2].
Furthermore, those currently in use, such as CA125 and PSA for
ovarian and prostate cancer respectively, are substantially limited
by high false positive rates and over-diagnosis [3,4]. A major
hurdle to the development of novel blood based biomarkers has
been the technical challenge of interrogating the plasma proteome
[5]. Another obstacle has been the choice of case/control
comparisons in biomarker discovery [6]. Levels of candidate
biomarkers from cancer patients are frequently compared to
healthy individuals. In these studies, it is difficult to control for
genetic or environmental variables, as well as non-cancerous
‘‘confounding’’ conditions. For example, inflammation and
angiogenesis are hallmarks of cancer, but also occur during
infections, chronic inflammation, auto-reactive diseases and other
conditions that are not specific to cancer [7]. While some
biomarker studies have used inflammatory conditions as controls
[8,9], this does not obviate the need to determine the range of
proteins that occur with inflammatory conditions. Indeed, the fact
that many candidate cancer biomarkers lack sufficient specificity to
be useful argues for a new approach [1,6].
Inflammation and angiogenesis play important roles at all stages
of cancer progression, including tumor initiation, growth, and
metastatic dissemination. Indeed, chronic inflammatory conditions
are strong risk factors for cancer [10]. Inflammation incites and
promotes carcinogenesis by causing cell and genome damage,
stimulating cellular turnover via cytokines and growth factor
release, and creating a tissue microenvironment that can enhance
invasion, migration and angiogenesis. Finally, the immune system
also controls cancer progression through immunosurveillance and
immunoediting [11]. Inflammation is a complex process enacted
by the host to control tissue damage against pathogenic, traumatic,
or toxic injury and is generally categorized into an acute, rapid
response, a sub-acute transition phase, and a persistent but slowly
evolving chronic condition. The acute inflammatory response
involves a rapid delivery of blood components, plasma, neutro-
phils, and leukocytes to the site of infection or injury, followed by
an influx of macrophages to resolve and repair the injury [12].
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19721Acute phase proteins found in the plasma are defined as either
positive or negative depending on whether they increase or
decrease during an inflammatory disorder. If an acute inflamma-
tory response fails to resolve the damage, a transition is made to an
evolving subacute stage, then to a chronic inflammatory condition.
Chronic inflammation, such as that seen in some autoreactive
conditions, may be ‘‘active’’. This is characterized by tissue
remodeling, macrophages, T and B cells, angiogenic and other
factors. Chronic inflammation can, in turn, lead to excessive tissue
damage, immune deregulation, and autoimmunity [10,13].
Angiogenesis, the sprouting of new blood vessels from
preexisting vasculature, is required to provide oxygen and other
nutrients to support tumor growth; and the degree of vasculari-
zation is a prognostic factor that correlates with tumor
aggressiveness [14]. However, angiogenesis is also associated with
non-cancerous conditions such as wound healing, tissue repair,
rheumatoid arthritis, and other chronic inflammatory diseases
[15]. Thus, inflammation and angiogenesis are intimately involved
in cancer as well as other common pathologies. These conditions
trigger complex and dynamic systemic responses, but the extent of
overlap between the systemic response to cancer and to non-
cancerous conditions is largely unknown.
To characterize the systemic response to cancer and inflam-
mation, we applied plasma proteomics to mouse models of
subacute inflammation, chronic inflammation, and angiogenesis.
Mouse models overcome some key hurdles for biomarker
discovery, including technology development [16]; more precise
matching of cases and controls to reduce genetic, age, and
environmental variables; interrogating the dynamic changes in
the plasma proteome through disease progression; and integrat-
ing results with the extensive biological knowledge bases [17].
Carrageenan injections were used to model subacute inflamma-
tion [18]. This model represents a subcuticular response of
evolving local irritation and necrosis similar to what might be
seen following tumor necrosis. For chronic inflammation, we
utilized a collagen-induced model of arthritis [19]. This model is
associated with antigen-antibody complexes, consistent with an
auto-reactive lesion, with infiltration of mononuclear cells, bone
remodeling, fibroplasia and vascular growth surrounding the
joint. FGF injections were used to stimulate angiogenesis,
resulting in rapid in-growth of blood vessels and supporting
stromal elements [20].
A large number of plasma proteins changed in abundance in
each model, reflecting the complex biology of each condition.
These plasma profiles were compared to those previously
identified in two well characterized mouse models of pancreatic
[21] and breast cancer [22]. In the breast cancer model, the
oncoprotein polyoma middle T antigen (PyMT) is driven by the
MMTV LTR and is restricted to the mammary epithelium. These
mice develop carcinomas that resemble human breast cancer and
that are associated with leukocyte infiltration and subsequent
pulmonary metastasis [23]. Development of pancreatic cancer in
the Pdx1-Cre Kras
G12D Ink4a/Arf
lox/lox model involves progres-
sion from pancreatic intraepithelial neoplasia (PanINs) to pancre-
atic ductal adenocarcinoma (PDAC), faithfully recapitulating the
human disease [24]. Here we show that the majority of plasma
protein changes identified in these tumor models were unique to
each model and not seen in the confounder models. Furthermore,
many of these proteins have known roles in cancer progression.
The identification and characterization of protein profiles
associated with cancer versus non-cancerous pathologies can be
used to understand the complex biology of the host response to
cancer and to prioritize candidate biomarkers that are associated
with cancer.
Materials and Methods
Animal studies
Animal studies were performed under IACUC regulations as
approved by the FHCRC animal use committee (Protocol #1311).
Ten female FVB mice were used for each condition paired with
ten littermate untreated controls. To model acute inflammation
that transitions into subacute inflammation, we used a well known
pro-inflammatory irritant, carrageenan, a carbohydrate derived
from seaweed [18]. This was delivered via a sponge implant which
sustains the carrageenan release and contributes a classical foreign
body response. 10610 mm surgical sponges were injected with 1%
carrageenan (Sigma C1867-5G) and implanted subcutaneously
into the right flank. Plasma was collected by cardiac puncture 3
weeks later. The plasma proteins identified from these mice should
correspond to a late stage subacute response to the carrageenan
and associated sponge impact, rather than to initiation of the acute
inflammatory response which occurs within 72 hours. To evaluate
the protein profile associated with chronic inflammation, we used
a collagen-induced arthritis mouse model [19]. Bovine collagen
type II (CII) (BD Biosciences, San Jose, CA) was emulsified with
complete Freund’s adjuvant (Pierce, Rockford, IL) at a final
concentration of 4 mg/ml and a total of 0.1 ml was injected
intradermally near the base of the tail. This results in the
development of chronic arthritis in the hind paws within 14–21
days. Mice were monitored every 2–3 days for the development
and progression of arthritis and plasma collected upon develop-
ment of swollen hind paws at 4 weeks. To model angiogenesis,
matrigel (BD Biosciences, San Jose, CA) plus FGF (500 ng/ml)
(Invitrogen, Carlsbad, CA) was injected subcutaneously into the
right flank resulting in rapid in-growth of blood vessels and
supporting stromal elements but with little associated inflamma-
tion [20]. Plasma was collected 3 weeks later. For these models,
blood from experimental and control mice was collected by
cardiac puncture, using a 1 cm
3 syringe and a 23 g needle, and
placed in a K3-EDTA tube (Webster Veterinary Supply, Sterling,
MA) [17]. Plasma was isolated by centrifugation at 20006g for
5 min and aliquots transferred to cryovials and frozen at 280uC.
Sample collection for the pancreatic [21] and breast [22] cancer
mouse models has been previously described. Briefly, mice for
pancreatic cancer proteomic analysis were obtained by breeding
Pdx1-Cre Ink4a/Arf
lox/lox and Kras
G12D Ink4a/Arf
lox/lox mice. Exp-
erimental Pdx1-Cre Kras
G12D Ink4a/Arf
lox/lox mice and control
Kras
G12D Ink4a/Arf
lox/lox and Pdx1-Cre Ink4a/Arf
lox/lox mice were
sacrificed at 5.5 and 7 weeks of age. For both case and control
mice, lethal comas were induced by injecting mice i.p. with a 0.6–
0.8 mL 5% Avertin (2,2,2-Tribromoethanol, Sigma). This differ-
ence in euthanasia method introduces a potential, although likely
minor, caveat when comparing the pancreas models to the other
models. A 1-mL syringe with a 22 g needle was used for cardiac
puncture to obtain blood. Blood was placed in K3-EDTA tubes
(Fisher) and centrifuged at 4uC for 5 min at 3000 rpm. Plasma was
removed and stored at 280uC.
For the breast cancer mouse model, transgenic FVB/N-
Tg(MMTV-PyVT)634Mul/J (PyMT) mice were obtained from
the National Cancer Institute and bred in-house to obtain plasma
samples from tumor-bearing mice and control littermates at two
time points of breast cancer development. PyMT heterozygote
males were crossed to FVB wild-type females to generate the
cohort of PyMT heterozygote and wild-type females for study. To
avoid bias, PyMT transgenic and control mice were paired at
weaning and were matched with respect to age, litter, and cage.
All mice were fed standard chow (Harland Tekland, 8664) and
acidified water ad libitum and kept on a 12 h light–dark cycle.
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to detect breast tumor growth. Breast tumors were allowed to
develop to either 0.5 or 1 cm in diameter, after which each tumor-
bearing mouse and a control were euthanized back-to-back on the
same day by CO2 inhalation. Blood was obtained by cardiac
puncture and plasma was isolated and stored as described for the
inflammation and angiogenesis mouse models.
Immunodepletion of abundant proteins and isotopic
labeling
50 ml of plasma from 5 mice was pooled for each set of case and
control samples. Pools were immunodepleted of the top three most
abundant proteins (albumin, IgG, and transferrin) using a MS-3
column (4.6610 mm, Agilent). The immunodepletion column was
equilibrated with buffer A at (0.5 ml/min) for 13 min and aliquots
of pooled sera were injected after filtration through a 0.22 mm
syringe filter. The flow-through fractions were collected for 10 min
at a flow rate of buffer A of 0.5 mL/min, combined and stored at
280uC. The column bound material was recovered by elution for
8 min with buffer B at 1 ml/min. Subsequently, immunodepleted
samples were concentrated using Centricon YM-3 devices
(Millipore Corp, Bedford, MA) and re-diluted in 8 M urea,
100 mM Tris pH 8.5, 0.5% OG (octyl-beta-d-glucopyranoside,
Roche). Following depletion and buffer exchange, protein
concentrations were determined by Bradford assays: angiogenesis
2.5 mg (case) and 3.8 mg (control), chronic inflammation 4.3 mg
(case) and 3.8 mg (control), and acute inflammation 2.8 mg (case)
and 3.1 mg (control), and the entire amount of protein for each
sample was used for subsequent acrylamide labeling. Samples were
reduced with DTT (0.66 mg DTT/mg protein), and isotopic
labeling of cysteine residues on intact proteins was performed.
Control samples were labeled with light 12C acrylamide isotope
(7.1 mg/mg protein) (.99.5% purity, Fluka), and experimental
samples were labeled with the heavy 13C-acrylamide isotope
(Cambridge Isotope Laboratories, 7.4 mg/mg protein) for 1 h at
room temperature. Pools of control and experimental samples
were then combined for intact protein separation.
Intact protein separation
The combined isotopically labeled samples were separated by an
automated online 2D-HPLC system controlled by Workstation
Class-VP 7.4 (Shimadzu Corporation). The combined labeled
plasma samples were separated in the first dimension on an anion
exchange column (Poros HQ/10, 10 mmID6100 mL, Applied
Biosystems) using an 8 step-elution (from 0 mM NaCl to 1000 mM
NaCl) at 0.8 mL/min. Fractions from each of the 8 anion-exchange
separation elution steps were automatically transferred onto a
reversed-phase column (PorosR2/10, 4.6 mm ID6100 mL, Ap-
plied Biosystems) for a second dimension of separation. A 25 min
gradient elution (from 5% to 95% mobile phase B) was used at
2.4 mL/min. 3 fractions were collected per minute, with each
fraction containing 800 uL. 576 reversed phase fractions were
collected in total (8 anion exchange fractions each separated into 72
reversed phase fractions). Mobile phase A for anion-exchange
chromatography consisted of 20 mM Tris (Sigma), 6% isopropanol
(Fisher), 4 M urea, pH 8.5 and mobile phase B was the same
composition and pH as A with 1 M NaCl (Fisher) added. Mobile
phase A for reversed-phase chromatography consisted of 95%
water, 5% acetonitrile, 0.1% TFA (Supelco), and mobile phase B
consisted of 90% acetonitrile, 10% water, 0.1% TFA.
Mass spectrometry analysis
In-solution digestion was performed with lyophilized aliquots
from the reversed-phase (second dimension) fractionation step.
Proteins in individual fractions were re-suspended in 0.25 M urea
(Fisher) containing 50 mM ammonium bicarbonate and 4%
acetonitrile and then digested overnight with 200 ng of modified
trypsin (Promega) at 37uC. The resulting peptide mixtures were
acidified with 5 mL of 1% formic acid. Aliquots were subjected to
mass spectrometry shotgun analysis after pooling of several
consecutive fractions (protein concentration estimated by UV
trace). 12 pools of individual reversed-phase fractions for each of
the 8 anion exchange steps were created by combining the
following sequential fractions: 1–22, 23–24, 25–26, 27–28, 29–30,
31–32, 33–34, 35–36, 37–38, 39–40, 41–42, and 43–72. 96
fractions were analyzed for each experiment by a LTQ-Orbitrap
(Thermo) mass spectrometer coupled with a NanoLC-1D
(Eksigent). The liquid chromatography separation was performed
in a 25 cm column (Picofrit 75 mm i.d., New Objectives, packed
in-house with MagicC18 resin) using a 90 min linear gradient
from 5 to 40% of acetonitrile in 0.1% formic acid at 300 nl/min
for shotgun analysis. Approximately 10 ug of protein was injected
per fraction. Spectra were acquired in a data-dependent mode in
m/z range of 400–1800, including selection of the 5 most
abundant +2o r+3 ions of each MS spectrum for MS/MS
analysis. Mass spectrometer parameters were capillary voltage of
2.0 KV, capillary temperature of 200uC, resolution of 60,000, and
target value of 1,000,000.
Data processing
Acquired data were automatically processed by the Computa-
tional Proteomics Analysis System (CPAS) [25] pipeline using the
X!Tandem search algorithm [26] configured with comet score
module plug-in. PeptideProphet [27] and ProteinProphet [28]
were used for validation of search results and protein inference.
Quantitation was performed using the Q3 quantitation tool [29].
The tandem mass spectra were searched against version 3.48 of
the mouse IPI database [30]. All identifications with a Peptide-
Prophet probability greater than 0.2 were submitted to Protein-
Prophet, and the subsequent protein identifications were filtered at
a minimum 5% error rate. For quantitation, ratios for proteins
were computed using only those peptides achieving PeptidePro-
phet probability of at least 0.75. Protein groups assigned by
ProteinProphet were combined by common gene symbol and
henceforth referred to as ‘‘protein’’. Case/control ratios for each
protein were computed by averaging log2 ratios across all peptides
assigned to the protein. Over 1,000,000 MS/MS spectra were
collected and proteins with 2289 unique gene names were
identified across the 3 experimental models.
Statistical significance of protein quantification by mass
spectrometry was determined by two methods. For proteins with
multiple paired MS events of heavy and light acrylamide, a one-
sample t-test was used to calculate a p-value for the mean ratio of
the whole protein across all fractions. Second, the probability for
the ratio for each MS event was calculated from the distribution of
ratios in a control-control experiment in which the same sample
was split and labeled with heavy and light acrylamide. If the p-
value for each individual event was ,0.05, the protein ratio was
considered statistically significant.
Network analysis
The increased and decreased proteins identified from the IPAS
analysis were used for biofunction and pathway analysis using
Ingenuity Pathway Analysis (IPA) Software (Ingenuity Systems,
Mountain View, CA). The IPA database consists of proprietary
ontology representing 300,000 biologic genes, proteins, and
molecular and cellular processes.
Proteomics of Systemic Inflammatory Response
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Plasma levels of Pf4, Igf1, Igfbp5, and Lcn2 were measured
using commercially available mouse DuoSet kits obtained from
R&D Systems (Minneapolis, MN). Plasma was diluted 1:1000,
1:400, 1:120, and 1:180 for Pf4, Igf1, Igfbp5, and Lcn2,
respectively, for testing. Assays were performed according to the
manufacturer’s protocol and samples were assayed in duplicate.
Results
Identification of plasma proteins distinct to tumor-
bearing mice
To identify cancer-restricted plasma proteins, we compared the
plasma proteomes of mice with carageenan-induced subacute
inflammation, collagen-induced arthritis, and FGF-induced
angiogenesis to the plasma proteomes of mice with PyMT driven
breast cancer and Pdx1-Cre Kras
G12D Ink4a/Arf
lox/lox pancre-
atic cancer. Plasmas obtained from mice with subacute
inflammation, chronic inflammation, and angiogenesis, along
with aged-matched control mice were subjected to in-depth
proteomic analysis. In proteomic comparisons of plasmas from
mice with confounding condition to control mice, between 378 to
511 proteins were quantified based on differential isotopic
labeling on cysteine residues (Table S1). Variability in the
number of quantified proteins reflects variability in protein
measurement and mass spectrometry sampling. Remarkably,
approximately one third of all quantified proteins changed in
abundance by 1.25-fold or greater compared to control mice
(p,0.05) and, of these, two to three times as many were
decreased as opposed to increased in all three models (Table 1,
Figure S1). When we consider only proteins quantified in all three
mouse models, comparisons of plasma profiles between the
models revealed a 35% overlap in altered proteins between
subacute and chronic inflammation models, compared to only a
15% overlap between the inflammation models and the
angiogenesis model (Table 1). Due to the limited sampling of
the mass spectrometer, a number of proteins were not quantified
in all three mouse models. When we do not require proteins to be
quantified in all three mouse models, the overlap of up- and
down-regulated proteins is shown in Figure 1A and 1B
respectively. Comparisons of changes in protein levels for each
model revealed a strong correlation between subacute and
chronic inflammation, with a Pearson test score of 0.67
(Figure 1C), while comparisons of each inflammation model to
the angiogenesis model revealed less than 50% correlations
(Pearson test scores of 0.49 and 0.31, respectively). Thus, plasma
profiles were more similar between inflammation models than
between angiogenesis and either inflammation model, reflecting
the underlying biology of these conditions. Further, the majority
of altered proteins were unique to each confounder model,
demonstrating biological specificity. The relative abundances of
the individual proteins identified in each of the three models are
listed in Table S1.
We then compared the proteomic profiles of these confounding
models to previously obtained profiles from early and late stage
breast cancer [22], and to profiles from early stage (PanINs) and
late stage (PDAC) pancreatic cancer [21]. In contrast to the
confounder models, a roughly equal number of proteins were
increased and decreased in tumor-bearing mice compared to
non-tumor-bearing mice (Table 2). Of these altered proteins, the
great majority (.75%) were not altered in confounders (Table 2).
Three patterns of plasma protein distribution were observed:
increased in both the confounders and the cancer models
(Figure 2A), increased in confounders but unchanged or
decreased in cancer (Figure 2B), and decreased in confounders
and increased in cancer (Figure 2C). Only 27% of proteins with
altered levels in the study were increased in both confounders and
cancer, while the largest category, accounting for 55% of the
total, consisted of proteins that were decreased in confounders
but increased in tumor-bearing mice. Relative levels of repre-
sentative proteins displaying these patterns are shown in Figure 3.
Note, lysyl oxidase like 1 (Loxl1) and proteoglycan 4 (Prg4) are
reduced in plasma from confounders and increased in both breast
and pancreatic tumor-bearing mice, while fatty acid synthase
(Fasn) and lipocalin2 (Lcn2) are increased in both confounders
and cancer models (Table S1).
To verify the differential abundance observed by mass spectrom-
etry, ELISA assays were performed on selected proteins based on
commercial availability (Pf4, Igf1, Igfbp5, and Lcn2) (Figure 4).
Note,insulin like growthfactor1 (Igf1)andinsulinlikegrowthfactor
binding protein 5 (Igfbp5) were decreased or unchanged in
confounders but increased in breast tumor-bearing mice. Lipocalin
2 (Lcn2) was increased in all models but to a higher level in tumor-
bearing mice, while platelet factor 4 (Pf4) was decreased in subacute
inflammation but increased in chronic inflammation and cancer.
Other plasma proteins that were specifically increased in tumor-
bearing mice included acetyl-CoA acetyltransferase 1 and 3, fatty
acid binding proteins 1 and 4, fibulin, peroxiredoxins 1, 5 and 6,
SPARC, and thrombospondins 1 and 4.
Plasma protein changes observed with inflammation
We next analyzed the altered plasma proteins from each
confounder condition. In the subacute inflammation model,
greater than 50% of the increased proteins play a known role in
inflammation, including positive acute phase proteins [31], as well
as the chemokines Ccl8 and Pf4 (also known as Cxcl4) (Table S1).
Among the decreased proteins were five complement proteins, as
well as secreted signaling proteins such as Rbp4, Igf1, Igf2, TGFb,
and Pdgfb. The complement cascade is important in the acute
phase response, while Igf1 and Rb4 are negative acute phase
proteins. Network analysis linked many of the proteins with altered
levels to intracellular (NF-kB) and secreted (Il-1 and TGFb)
immune system regulators (Figure 5A, B) [10]. TGFb itself was
reduced, as were multiple proteins involved in TGFb signaling.
Collectively, proteomic analysis of plasma identified known acute
phase proteins, proteins linked to inflammatory regulators such as
TGFb, and additional proteins (e.g. cytoskeletal proteins actins,
cofilins, vasp, profilin, and destrin) not previously linked to
inflammation (Table S1).
As in the subacute inflammation model, a significant number of
proteins increased under chronic inflammation had known links to
Table 1. Comparison of proteins identified in plasma from
the 3 mouse models.
Number of proteins*
Identified Quantified Increased** Decreased**
Acute
inflammation
1611 411 56 135
Chronic
inflammation
1706 511 47 148
Angiogenesis 1255 378 20 65
*Unique gene names.
**Case compared to control (1.25-fold or greater, p-value,0.05).
doi:10.1371/journal.pone.0019721.t001
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proteins were identified than with the subacute model (Table S1).
Another major category of proteins altered with chronic
inflammation are involved in extracellular matrix remodeling
(Figure 5C). Many of these were decreased and are targets of the
Mmp2 protease, which was itself increased. As in the subacute
model, TGFb and proteins linked to its regulation or signaling
were reduced, including Ltbp1, Ltbp4, and Vasn (Figure 5D).
Figure 1. Comparison of plasma proteomic changes in confounding models. Venn diagrams comparing (A) increased and (B) decreased
proteins in plasma from the subacute and chronic inflammation and angiogenesis models as compared to control mice. Diagrams show numbers of
proteins, either elevated or reduced in each model, and which are unique or shared between each of the 3 models. The majority of either increased or
decreased proteins were unique to each model. (C) Correlation plots for quantified proteins. Case/control (log2) ratios for each quantified protein are
plotted on the X- and Y- axes. The plots reflect abundance differences of specific proteins between two models. Proteomic comparisons between
chronic versus subacute inflammation comparison are more similar (R=.67) than are comparisons between either inflammation model and the
angiogenesis model (R=.49 and .31, respectively).
doi:10.1371/journal.pone.0019721.g001
Table 2. Comparison of quantified proteins from confounding and tumor models.
Acute Chronic Angiogenesis
inflammation inflammation
Tumor model **** # Proteins* # Proteins shared with tumor models
PyMT 0.5 cm** Up 94 13 6 4
Down 111 12 11 5
PyMT 1.0 cm** Up 192 13 11 4
Down 127 6 13 7
PanIN*** Up 89 11 11 3
Down 129 17 18 6
PDAC*** Up 141 15 13 1
Down 194 26 21 17
*Unique gene names.
**As reported in J. Proteome Res. 2008, 7, 1481–1489.
***As reported in PLoS Med. 2008, 5, e123.
****Up and down refers to case compared to control (1.25-fold or greater, p-value,0.05).
doi:10.1371/journal.pone.0019721.t002
Proteomics of Systemic Inflammatory Response
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A significant number of the altered proteins identified in the
angiogenic model have known mechanistic links to angiogenesis
and/or are expressed in endothelial cells, such as thrombospondin
1 and 4, renin 1 and 2, platelet factor 4, trefoil factor 1, and
collagen binding protein 2, as well as other proteins not previously
associated with angiogenesis. In addition, alterations in comple-
ment proteins and coagulation factors, which have links to
angiogenesis, were observed (Figure 5E) [32] [33]. Many proteins
involved in TGFb signaling, including TGFb itself, were reduced
(Figure 5F).
Only three proteins were increased in all three models: Hp,
Ccl8, and Fasn, all of which are known to be activated and
increased during inflammatory responses [34–36]. There were ten
decreased proteins shared among the models: C8a, Car3, Ddt,
Ltbp1, Mug1, Notch1, Proz, Rbp4, Tagln, and TGFb. Interest-
ingly, at least four of these are mechanistically linked, in that Ltbp1
and Tagln are involved in the regulation of TGFb [37] and there
is cross talk between Notch1 and TGFb signaling [38].
Discussion
Successful development of plasma-based biomarkers for early
detection of cancer requires that the markers have both high
specificity and sensitivity. In particular, any marker must
discriminate between non-cancerous conditions and cancer. Many
cancer biomarkers discovered to date lack sufficient specificity and
cannot adequately distinguish cancer from confounding conditions
[6]. Here, we demonstrate a strategy to identify cancer-associated
plasma proteins by controlling for confounding factors. By
applying state-of-art proteomic analysis to well defined mouse
models, we have identified and quantified approximately 500
plasma proteins associated with subacute inflammation, chronic
inflammation, and angiogenesis. Approximately one third of all
quantified proteins from these confounder models showed a
significant change in abundance, indicating that a significant
fraction of the plasma proteome changes during a systemic
response. The majority of proteins that changed in abundance
were unique to each condition and these accurately reflect the
complex underlying biology.
Changes in the plasma proteome from the confounding
condition models were compared to the plasma proteomes from
two mouse cancer models. Overall, approximately 25% of the
proteins altered in the confounder mice were also altered in the
tumor bearing mice, reflecting the central roles of both
inflammation and angiogenesis in tumor development. In
particular, proteins of the fibrinogen cascade, ITIH trypsin
inhibitors, haptoglobin and hemopexin predominated across
models. These proteins are less likely to be cancer-specific and
this list can be used to prioritize cancer associated proteins. For
example, lipocalin 2 (Lcn2), a small extracellular protein involved
in iron transport, has been shown to promote breast cancer
progression and metastasis and is found in urine of patients with
metastatic breast cancer [39]. Based on these findings, Yang et al.
have proposed that Lcn2 may be a biomarker for breast cancer
[40]. However, Lcn2 plasma protein levels were elevated under
Figure 2. Heat map of plasma proteins altered in both
confounders and cancer models. (A) Proteins increased in both
confounders and cancer models compared to controls (.1.25 fold,
p,0.05), (B) proteins increased in confounders and decreased in cancer
models, and (C) proteins decreased in confounders and increased in
cancer models (red=up, green=down, black=no change, grey=not
quantified).
doi:10.1371/journal.pone.0019721.g002
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usefulness as a cancer-specific biomarker. Haptoglobin (Hp) has
also been suggested as a biomarker for ovarian cancer [41] but we
observed elevated levels of Hp in all confounder models. It should
be pointed out that our mass spectrometry analysis does not
necessarily distinguish between specific isoforms of the same
protein and we cannot rule out the presence of ‘‘cancer-specific’’
isoforms of proteins such as haptoglobin.
The majority of the proteins altered in plasma from the tumor
bearing mice did not overlap with the three confounding
models. This suggests that most of the alterations in the plasma
proteome found in tumor bearing mice are specifically
associated with cancer. A caveat to this conclusion is that
cancer-associated inflammation may significantly differ from the
models of inflammation we used here. Also, inflammation
associated with early stage cancer is likely to differ from that
associated with late stage disease. Of the proteins that differed
between confounder and cancer models, the largest category
consisted of proteins that were decreased in confounders and
increased in cancer. An examination of the proteins in this
category reveals many with known associations to breast or
pancreas cancer biology, but most have not been reported as
altered in plasma. For example, alpha-S1-casein (Csn1s1) is a
breast-specific milk protein. Lysyl oxidase (Loxl1), a matrix
remodeling protein, is known to play a role in breast cancer
migration, adhesion, and metastasis [42]. Insulin like growth
factor-1 (Igf-1) signaling promotes proliferation and inhibits
apoptosis of breast cancer cells, and high plasma levels of Igf-1
are associated with risk of breast, prostate and other cancers
[43]. Insulin like growth factor binding protein 5 (Igfbp5) plays
multiple roles in breast cancer progression and is a prognostic
factor [44]. Thrombospondin-1 (Thps1), a potent inhibitor of
Figure 3. Comparisons of selected proteins in plasma from confounders and cancer models. Plots show mass spectrometry based log2
case/control ratios for specific proteins in each confounder and cancer model that display differential abundance patterns. Loxl1 represents proteins
that are reduced in the confounders and elevated in the cancer models. Fasn shows elevation in all models but more so in PanIN. Prg4 is elevated
primarily in the pancreatic cancer model. Lcn2 is elevated in the inflammation and to a greater degree in the cancer models, but not the angiogenesis
model.
doi:10.1371/journal.pone.0019721.g003
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Fibulin 2, an extracellular matrix and plasma glycoprotein,
facilitates invasion and migration of breast cancer cells [46].
SPARC, a secreted protein involved in cell/matrix interactions,
is overexpressed in pancreatic cancer [47]. Other proteins
increased in tumor-bearing mice include fatty acid binding
proteins 1 and 4, acetyl-CoA acetyltransferase 1 and 3, and
peroxiredoxins 1, 5 and 6. This analysis shows that controlling
for confounding conditions can be used to identify and prioritize
plasma proteins whose abundance changes with cancer. Future
studies will be required to determine the role of these proteins in
the plasma with respect to cancer biology and to validate these
as cancer specific biomarkers.
Proteomic analysis of plasma also provides biologic insight into
the systemic response to inflammation and angiogenic stimuli.
Many of the altered proteins from each confounder model
grouped into functional categories that are known to participate
in the systemic response to these conditions, as well as novel
inflammation or angiogenesis-related proteins. For example, in the
subacute inflammation model, alterations in plasma proteins were
detected from all major functional categories of the acute phase
response, including complement system, coagulation, and fibrino-
lytic systems, antiproteases, transport proteins, and other partic-
ipants in the inflammatory response [31]. This is consistent with
the complex and rapidly evolving changes present during this stage
of an irritant and foreign body driven inflammatory process.
Figure 4. Quantitative analysis of selected proteins increased in cancer and inflammation mouse models. ELISA analysis of Pf4, Igf1,
Igfbp5, and Lcn2 showing increased plasma concentration in PyMT breast tumor-bearing mice compared to either the subacute or chronic
inflammation mice. Plasma from untreated mice was used as the control.
doi:10.1371/journal.pone.0019721.g004
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immune regulators such as TGFb were also seen. The most
increased protein identified was Slit-2, a secreted protein that
modulates inflammation and inhibits neutrophil migration [48].
Slit, through binding to its receptor Robo inhibits Rho GTPase,
which may contribute to the decrease in a number of cytoskeletal
proteins seen during inflammation. The chronic inflammation
plasma proteome was also dominated by inflammatory proteins
but many differed from the subacute model, indicating distinct
mechanisms of action and systemic responses to these inflamma-
tory conditions. As expected, a number of altered proteins
identified have links to arthritis, including Mmp-2, TGFb, Fstl1,
Figure 5. Network analysis of plasma proteins from confounding conditions. Top networks assigned by Ingenuity Pathway Analysis for
both increased and decreased proteins from the subacute inflammation (A, B), chronic inflammation (C, D) and angiogenesis models (E, F). Networks
for the subacute model show abundant fibrinogen and ECM proteins, the chronic model gives prominent growth factor and collagen networks, while
the angiogenesis network shows chemokine and coagulation proteins. [red=increased, green=decreased, white=no change in abundance in cases
vs control mice, .1.25 fold p,0.05.].
doi:10.1371/journal.pone.0019721.g005
Proteomics of Systemic Inflammatory Response
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included those involved in angiogenesis or vascular and connective
tissue biology, including complement and coagulation factors.
A number of proteins identified in all three confounding
conditions are involved in TGFb signaling networks with direct
links to the regulators Ltbp1 and 4. TGFb is a secreted cytokine
involved in many cellular processes, including cell proliferation,
extracellular matrix remodeling, cell migration, adhesion, inva-
sion, and metastasis [50]. TGFb is known to play dual roles in the
inflammatory response, both inhibitory and promoting, and is also
linked to vascular biology [37]. The opposing roles for TGFb are
likely controlled by its selective production and latency, in addition
to receptor modulation and differential susceptibility of target cells
at various stages of development. Previous studies have shown that
latent circulating TGFb may have protective properties against
inflammation. Indeed, systemic administration of TGFb alleviates
the inflammatory response in a mouse model of arthritis [51] and
impaired TGFb signaling during infection with E. coli enhanced
peritoneal inflammation in a rat model [52]. That TGFb and a
number of its interacting proteins are altered in plasma from all
three models confirms the central role of TGFb in inflammation
and angiogenesis. However, some TGFb-related proteins exhib-
ited model specificity implying that the TGFb response is tailored
to each condition.
In summary, by applying plasma proteomics to mouse models
of disease, we identified novel proteins and protein networks that
are involved in the systemic response to both cancer and non-
cancerous conditions. By identifying proteins involved in the
systemic response of non-cancerous conditions, the specificity of
potential cancer biomarkers can be better assessed.
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